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Gene regulationted that ER-α can inﬂuence the activity of the MMP-13 promoter. ER-α activity is
mediated by two separate transcriptional activation domains (AF-1 and AF-2). The present study focused on
analyzing the roles of these domains on the activation of the MMP-13 promoter. Transfection of synoviocytes
with an ER-α construct lacking the C-terminus AF-2 domain led to signiﬁcant elevation in MMP-13 promoter
activity compared to wild type ER-α. Progressive deletions in the N-terminal AF-1 domain led to signiﬁcant
losses in MMP-13 promoter activity. MMP-13 promoter mutagenesis indicated that an AP-1 regulatory site
was essential for ER-αmutant activity. Thus, both AF-1 and AF-2 domains of ER-α are required for regulation
of MMP-13 promoter activity. As ER variants and ER related proteins have been implicated in bone and joint
disorders, these ﬁndings provide understanding of the possible role of ER variants in the development of
such conditions.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionSubsets of women are prone to developing osteoarthritis (OA)
followingmenopausewhen estrogen levels in the body decline [1,2]. It
is well documented that the enzyme matrix metalloproteinase 13
(MMP-13) effectively degrades collagen which is the principal
constituent of cartilage, and thus may play a major role in the
pathogenesis of diseases such as osteoarthritis (reviewed in [3,4]).
Transgenic mice over-expressing MMP-13 show evidence of degrada-
tion of articular cartilage and exhibit joint pathology similar to that
found in OA [5]. Furthermore, studies have shown that ovariectomy of
rats leads to elevations in the expression of the rodent MMP-13 in
osteoblastic cells [6].
The expression of MMP-13 is low in the cartilage of normal
skeletally mature adults and this likely enables healthy connective
tissue remodeling without damaging the tissues [7]. However, in
osteoarthritis-like conditions the level of MMP-13 expression
increases considerably (including in synovium), resulting in aberrant
destruction of cartilage tissue [7–10]. Based on its importance in
normal and disease states, better understanding of the potential
mechanisms by which MMP-13 expression is regulated by ER-α (+/−
estrogen) may provide valuable insights into the onset and progres-
sion of OA, particularly in a subset of post-menopausal females.
The detection of estrogen receptors (ER) in several tissues of the
joint indicates that these tissues are likely responsive to the hormone
estrogen. Several studies have established the presence of both MMP-
13 and ER in joint tissues [11–15] and parallel in vitro studies have1 403 210 6066.
l rights reserved.indicated that both alpha and beta isoforms of ER (ER-α and ER-β) can
elevate the activity of the MMP-13 promoter and this modulation is
decreased depending upon whether or not the ER-α or ER-β is
complexed with estrogenic ligands [16,17]. It is well established from
previous studies that both the alpha and beta isoforms of ER function
as ligand-inducible transcription factors and regulate the expression
of estrogen responsive genes (reviewed in [18,19]). Transcriptional
activation or repression of genes by ER occurs through the estrogen
response element (ERE) or through ER tethering to other transcription
factors that act through the AP-1 or other transcriptional regulatory
sites often present in the promoter [20,21]. Recent studies have shown
that ER-α can regulate the expression of a member of the matrix
metalloproteinase family of genes — MMP-13, primarily through the
AP-1 transcriptional regulatory site [16].
ER-α is a modular protein that is comprised of six functional
domains denoted A–F, each with speciﬁc functions, such as ligand
binding, dimerization and DNA binding and trans-activation. The
activating potential of ER-α is mediated by two separate transcrip-
tional activation domains (AF-1 and AF-2) that allow it to stimulate
the transcription of speciﬁc genes [22]. The relative activities of the
AF-1 and AF-2 domains of ER-α vary depending upon the cellular
environment and the promoter of the speciﬁc regulated gene.
Furthermore, since the AF-1 and AF-2 domains are located at the
amino and carboxyl terminal ends of the protein, respectively,
synergism between the two AF sites via coactivators may also play a
role in exerting their inﬂuence on downstream promoters [23].
Further to this discussion, naturally occurring variants of ER that
lack the ligand binding exon, apparently through alternative splicing,
have been reported in breast cancer tissue [24] and in ligaments [11].
In addition, a family of estrogen receptor related proteins (ERR), also
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tissues [25]. Recent studies have indicated that expression of some of
these ERR can bemodulated in joint tissues during inﬂammatory joint
disease development [26]. Therefore, not only is it of interest to
understand the basic biology of ER variants, there may also be clinical
relevance to their presence.
The presence or absence of estrogen has an inﬂuence not only on
the MMP-13 activity in synoviocytes [16], but also on other MMPs
such as MMP-2, MMP-7 and MMP-9 which are expressed in tissues
such as the cornea [27]. With the aim of increasing our under-
standing of the role of ER in regulation of MMP-13, in the present
study we have analyzed the roles of the activation functions and
ligand binding domains of ER-α on the activation of the MMP-13
promoter in the presence and absence of estrogen in a rabbit syno-
viocyte cell line.2. Methods and materials
2.1. Cell culture
The rabbit synoviocyte cell line HIG-82 was obtained from the
American Type Culture Collection (Rockville, Md). Cells were main-
tained at 37 °C under 5% CO2 in Ham's F-12 Nutrient Media (Life
technologies) supplemented with 10% Fetal calf serum (InVitrogen
Canada Inc.) and 1% Penicillin/Streptomycin. Cells were subcultured
1:4 with 0.25% trypsin. This cell line was previously shown to be
negative for endogenous ER-α and ER-β expression [16,17].2.2. Construction of rabbit MMP-13 luciferase reporter vector
The promoterless pGL2 Basic luciferase reporter vector (Promega,
Madison, WI) was used to construct a plasmid containing the proximal
370 bpof the rabbitMMP-13promoter. TheMMP-13 promoter construct
p370-Luc was generated by PCR using a 5′-sense primer containing the
appropriateMMP-13 promoter sequencewith a Kpn-I site introduced at
the 5′-end and the same 3′-antisense primer 5′-CCAACAGTACCG-
GAATGCCAAGC-3′ (nucleotide 49 to 71) that corresponds to a pGL2
Basic sequence downstream of the multiple cloning site. The 5′-primer
used for p370-Luc construct contained MMP-13 sequence (underlined)
was −370 to −356 (5′-CGGGTACCATGGGCGTACACATA-3′).
PCR products were puriﬁed and precipitated by the QIA quick-spin
PCR puriﬁcation kit (Qiagen) and digested with KpnI/HindIII. The ﬁnal
product was then ligated into KpnI/HindIII digested pGL2 Basic and
transformed into E. coli (DH-5α). Mutations were introduced into
desired constructs using the Quick Change Site-Directed Mutagenesis
kit (Stratagene). The mutagenic oligonucleotide primers were
designed and synthesized for each mutant. The AP-1 site TGACTCA
was changed by mutating TGA to ACT at the ﬁrst three bases. The PEA-
3 site consensus sequence AGGAAGC was altered to AACAAGC and the
Runx domain binding sequence (RD site) AACCACA was changed to
AGACACA. All reporter plasmids were puriﬁed on EndoFree Plasmid
Maxi Kits (Qiagen, Mississauga, ON) according to the manufacturer's
instructions and subjected to sequencing analysis to verify the
orientation and accuracy of each construct.2.3. Additional control and ER-α expression plasmids
The internal control plasmid pRLSV40 was obtained from Promega
(Promega, Madison, WI). The pRLSV40 plasmid constitutively
expresses the Renilla form of luciferase under the strong SV40
promoter and thereby acts as an internal control in the dual luciferase
assay. The expression vectors for ER-α such as WT–ERα, E41, A87,
M109, ΔAB and ABCD were those used previously and were all
subcloned into the same vector, pCMV5 [28].2.4. Subcloning of ΔAB, ABCD into the pSG5 vector
The ΔAB and ABCD constructs were sub-cloned from pCMV5 [28]
to the pSG5 vector (Stratagene, USA). The sequence and orientation of
the sub-cloned fragments was conﬁrmed by sequencing.
2.5. Transient transfection and luciferase assay
The rabbit synoviocyte cell line, HIG-82, was transfected using the
FuGene6 Transfection reagent (Roche Molecular, Indianapolis. IN) as
directed by the manufacturer. HIG-82 cells were seeded on 12-well
plates on the 24 h before transfection at a density of 1×105 cells/well.
The cells were washed with PBS prior to transfection and then
transfected with a constant amount (1 μg) of reporter plasmids
(shown to be optimal in preliminary studies; data not shown),
pRLSV40 (50 ng) and WT–ERα or ABCD or ΔAB (0.25 μg–1 μg) using
the Fugene 6 reagent. Transfection was performed in Ham's F-12
Nutrient Medium in the absence of serum for a period of 24 h.
Immediately, after transfection, (10−12 to 10−8 M) 17β-estradiol (E2)
(Sigma, Oakville, ON) was added to the medium of appropriate wells
in speciﬁc experiments. Twenty four hours after transfection and (+/−)
ligand treatment, the medium was removed from the cells and the
cells were washed once with phosphate buffered saline (PBS). The
cells were then lysed directly in the wells with 1× Passive Lysis Buffer
(Promega Corp.). Luciferase activity was determined on cell lysates
using a Turner TD-20 illuminometer and the Dual Luciferase™
Reporter Assay kit (Promega Madison, WI). All transfection experi-
ments were repeated three or more times with results very similar to
those reported.
2.6. Western blotting
Western blotting was conducted on extracts of cells transfected
with eitherWTER-α (Full Length) or ABCD orΔAB, sub-cloned into the
pSG5 vector to assess ER protein being expressed in transfected cells.
Protein extracts of non transfected HIG-82 cells were used as negative
controls for ER expression. Cells were transfected as described above,
and were collected 24 h later. The cell pellet was washed with PBS
buffer (1×) and then protein was extracted using a mammalian cell
lysis kit (Sigma-Aldrich Inc., USA). Aliquots of protein lysates were
separated using 10% SDS-PAGE gels at 130 V for 70 min. The separated
proteins were then transferred to nitrocellulose membranes by
standard methods and incubated with optimal dilutions of rabbit
polyclonal antibodies for either the N-terminal of ER-α (H-184
obtained from Santa Cruz Biotechnology Inc. with epitope corre-
sponding to amino acids 2–185 mapping at the N-terminus of
estrogen receptor α) or the C-terminal of ER-α (HC-20 obtained
from Santa Cruz Biotechnology Inc with epitope mapping at the C-
terminus of ERα of human origin). The blots were washed 3× with PBS
buffer containing Tween20 (0.025%) and then incubated with the
secondary antibody (anti-rabbit HRP obtained from Amersham Inc,
USA). The Amersham ECL™western blotting reagents (GE Healthcare,
UK) were used to detect the bands.
2.7. Real time PCR analysis
Real Time PCR was performed to determine the inﬂuence of WT,
ABCD or ΔAB constructs of ER-α on endogenousMMP-13mRNA levels
in HIG-82 cells following transfection. HIG-82 cells were cultured on
6-well plates on the day before transfection at a density of 1×105 cells/
well. The following day, cells were transfected withWT–ERα, ABCD or
ΔAB at concentrations ranging from 0.25 to 1.0 μg. After 24 h of
transfection, cells were washed with PBS, total RNAwas isolated using
the TRIspin method [29] and then the SYBR® Green reagent was
subsequently used for ﬂuorometric quantiﬁcation of total RNA. One
microgram of total RNA from each sample was reverse transcribed
Fig. 1. (A) Diagrammatic representation of the structure of WT–ER-α with all the
functional domains (A–F), mutant ABCD without the ligand binding/AF-2 domains and
mutant ΔAB lacking the AF-1 domain. (B) Protein expression of WT–ER, ABCD and ΔAB
in HIG-82 cells. HIG-82 cells were transiently transfectedwith either 0.5 μg ofWT–ER or
ABCD or ΔAB and 24 h after transfection, cells were lysed and protein was extracted.
Following separation using SDS-PAGE gel and transfer of the gel to a nitrocellulose
membrane western blotting was performed. The panel on the left represents western
blot performed using rabbit polyclonal antibody ER-α (HC-20) to detect WT–ERα and
ΔAB and the panel on the right represents western blot performed using rabbit
polyclonal antibody, ERα (H-184) to detect ABCD form of ER-α and the WT–ERα. HIG-
82 cells were used as non-transfected negative controls in both cases (Control).
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random primers and Omniscript reverse transcriptase, and diluted to
500 μL/μg RNA. All samples in an experiment were subjected to RT at
the same time to avoid variability.
Real-time PCR was performed on the RT preparations with rabbit
speciﬁc PCR-primers for amplifying the MMP-13 (Forward primer: 5′-
TGGTCTTCTGGCTCACGCTT -3′ and Reverse primer 5′-ACTCTTGC-
CGGTGTAGGTGT-3′ and probe: 5′-TTGCTGCCCATGAGTTTGGC-
CATTCCTT-3′) and the housekeeping GAPDH gene (Forward primer
5′-GCAGGATGCGTTGCTGACAATCTT-3′ and reverse primer 5′-AGTAT-
GATTCCACCCACGGCAAGT-3′). The reaction mixture for quantiﬁcation
of GAPDH contained 7.5 μL RT (described above), 0.75 μL each of
forward and reverse primer (10 μM), 12.5 μL Bio Rad iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA), and 3.5 μL molecular biology grade
water, for a total reaction volume of 25 μL. For MMP-13 assessment,
the reaction mixture contained 0.75 μL each of forward and reverse
primer (10 μM) alongwith 2.5 μL of probe. Ampliﬁcation and detection
were performed using an iCycler Thermal Cycler (Bio-Rad, Hercules,
CA). The PCR program consisted of 3 min at 95 °C for Taq activation,
followed by 40 cycles of PCR ampliﬁcation (30 s at 95 °C, 30 s at 65 °C,
and 30 s at 72 °C) and 1 min at 95 °C. At the completion of each run,
melting curves for the amplicons were measured by lowering the
temperature slowly from 95 to 15 °C while monitoring ﬂuorescence.
The speciﬁcity of the PCR ampliﬁcationwas checked by examining the
melting curve (dF/dT vs temperature) for non-speciﬁc peaks. GAPDH
levels were used as a reference for normalization and relative
quantiﬁcation was analyzed using iCycler iQ Optical System Software
Version 3.0a (Bio-Rad, Hercules, CA).
2.8. Statistical analysis
Statistical analysis of the data was performed using ANOVA,
STDEVA, and STEYX in the Excel 5.0 software.
3. Results
3.1. Protein levels of WT–ERα, ABCD DNA and ΔAB expressed in the
transfected HIG-82 cells
The present study was focused on deciphering the possible roles
played by the functional domains of ER-α in the modulation of MMP-
13 promoter activity. A schematic representation of the different
domains present in the WT–ERα, ABCD and ΔAB constructs is shown
in Fig. 1A. The WT–ERα contains the N-terminal AF-1 domain, central
DNA binding domain and the C-terminal AF-2/ligand binding domain.
As depicted in Fig.1A, the ABCDmutant of ER-α is deﬁcient in the AF-2
and the ligand binding domains and the ΔAB is a mutant form of ER-α
in which the AF-1 domain has been deleted.
As a ﬁrst step, western blotting was performed to ensure that ΔAB,
ABCD and WT–ERα were expressed in the HIG-82 cells following
transfection. Prior to performing the western blotting, the ΔAB, ABCD
and WT–ERα were ﬁrst sub-cloned into the pSG5 vector from the
pCMV5 vector as described in Methods and materials. The protein
expression for WT–ERα and ΔAB was detected using the rabbit
polyclonal antibody (HC-20) which recognizes the C-terminal portion
of ER-α antibody (See Fig. 1B). As the ABCD construct is deﬁcient in
part of the C-terminus, hence it is not recognized by the HC-20
antibody. However, ABCD expression was detected when rabbit
polyclonal antibody (H-184) to the N-terminus of the estrogen
receptor α of human origin was used (see Fig. 1B). The results from
the western blot analysis indicate that ABCD, ΔAB andWT–ERα are all
expressed at somewhat similar levels in the HIG-82 cells. Therefore,
the increased or decreased levels of MMP-13 activity observed when
ABCD or ΔAB is the modulator is likely not due to overtly unequal
expression of ER-α mutants.3.2. Comparing the inﬂuence of increasing concentration of WT–ERα and
ABCD DNA on endogenous and exogenous MMP-13 promoter activity
Next, we examined the effect of WT–ERα and the ABCD mutant of
ER-α (lacking the hormone binding and AF-2 domain) on endogenous
MMP-13 mRNA levels in HIG-82 cells using real time PCR. Non-
transfected HIG-82 cells or cells transfected with increasing concentra-
tions (0.25, 0.5 and 1 μg) of WT–ERα or ABCD plasmid DNA were
analyzed 24 h post-transfection for MMP-13 mRNA. The results
presented in Fig. 2A indicate that endogenous MMP-13 expression is
inﬂuenced by the WT–ERα and ABCD mutant of the estrogen receptor
alpha as endogenous MMP-13 mRNA levels were found to signiﬁcantly
increase following transfection with increasing concentrations of DNA.
The results presented in Fig. 2A suggest that transfectionwith 0.25 μg or
0.5 μg of WT–ERα did not have a signiﬁcant impact on endogenous
MMP-13 mRNA levels, although MMP-13 mRNA levels did increase at
these DNA levelswhenABCDwas themodulator. However,mRNA levels
for MMP-13 were increased by ∼2.0 fold when the concentration of
WT–ERα was increased to 1 μg. A 2-fold increase in the endogenous
levels of MMP-13 was observed when 1 μg of ABCD was the modulator
compared to when 1 μg of WT–ERαwas themodulator. Thus, the ABCD
construct lacking the AF-2 domain was a more effective modulator of
endogenous MMP-13 mRNA levels than was the WT–ERα construct.
The ΔAB ER construct, lacking the AF-1 domain did not inﬂuence
endogenous MMP-13 mRNA levels at any of the concentrations tested
(data not shown), ﬁndings consistent with results presented below.
The effect of increasing concentrations of the mutant truncated
form of ER-α (ABCD) on MMP-13 promoter luciferase activity was
Fig. 3. Effect of increasing concentrations ofWT–ERα andmutant of ER-α (ΔAB) DNA on
theMMP-13 promoter activity in the absence of any ligand. Increasing concentrations of
WT–ERα DNA leads to corresponding increase in the MMP-13 promoter activity though
no signiﬁcant elevation in MMP-13 activity is observed when ΔAB is the modulator.
HIG-82 cells were transiently co-transfected with either WT–ERα or ΔAB at varying
DNA concentrations along with the rabbit MMP-13 DNA (p370-Luc 1 μg) and the
internal control plasmid, pRL-SV40 (0.05 μg). Luciferase activity was expressed as the
ratio of (p370-Luc) ﬁreﬂy luciferase activity and the (pRLSV40) Renilla luciferase
reporter activity. Values represent the mean +/− S.E. for three determinations.
‡Pb0.0005 as compared to control without the transfected WT–ERα. Pb0.0005
compared WT–ERα to ΔAB.
Fig. 2. (A) Effect of WT–ERα and ABCD on the endogenous levels of MMP-13 in the HIG-
82 cells. The mRNA levels for endogenous MMP-13 expressed prior to and after
transfection with WT–ERα or ABCD in HIG-82 cell line as determined by real-time PCR.
HIG-82 cells were either left un-transfected (No WT–ERα or ABCD) or were transiently
co-transfected with (0.25–1 μg) of WT–ERα or ABCD. After 24 h of transfection, total
RNAwas extracted from the cells and analyzed by Real-Time PCR. PN0.05 when
control without the transfected WT–ERα is compared to control without transfected
ABCD. Pb0.05 compare WT–ERα to ABCD. ‡PN0.05 (Non-signiﬁcant) when
control without the transfected WT–ERα is compared to values obtained from cells
transfected with increasing amounts of WT–ER-α. ♥Pb0.05 (Signiﬁcant) when control
without the transfected WT–ERα is compared to values obtained from cells transfected
with increasing amounts of WT–ERα. ♣Pb0.05 (Signiﬁcant) as compared to control
without the transfected ABCD. φPN0.05 (Not-Signiﬁcant) as compared to control
without the transfected ABCD. (B) Comparison of the effect of WT–ERα and ABCD
mutant on the MMP-13 promoter activity in the absence of any ligand. Increasing
concentrations of ABCD andWT–ERαDNA leads to corresponding increase in the MMP-
13 promoter activity. HIG-82 cells were transiently co-transfected with either WT–ERα
or ABCD at varying DNA concentrations along with the rabbit MMP-13 DNA (p370-Luc
1 μg) and the internal control plasmid, pRL-SV40 (0.05 μg). Luciferase activity was
expressed as the ratio of (p370-Luc) ﬁreﬂy luciferase activity and the (pRLSV40) Renilla
luciferase reporter activity. Values represent the mean +/− S.E. for three determinations.
Constitutive elevation in MMP-13 promoter activity is observed when ABCD mutant of
ER-α is present as a modulator. MMP-13 promoter activity is elevated more when ABCD
mutant of ER-α is the modulator as compared to the WT–ERα. ‡Pb0.0005 as compared
to control without the transfected WT–ERα. Pb0.0005 compare WT–ERα to ABCD.
♣Pb0.0005 as compared to control without the transfected ABCD.
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increasing concentration of WT–ERα. The HIG-82 cells were transi-
ently transfected with the WT–ERα or ABCD constructs at increasing
concentrations ranging from 0 to 1 μg, along with the p370-Luc MMP-
13 promoter and the internal control plasmid, pRLSV40 (see Fig. 2B).
After 24 h, the luciferase activities of the cell lysates were determined.
The results presented in Fig. 2B demonstrate that increasing
concentrations of ABCD and WT–ERα DNA led to corresponding
elevations in MMP-13 promoter activity. MMP-13 activity was
elevated to a greater extent under the inﬂuence of ABCD compared
to WT–ERα. MMP-13 promoter activity was increased by ∼30 fold by
1 μg of ABCD when present as the modulator, while only a ∼10 foldincrease was observed with the same concentration of WT–ERα (see
Fig. 2B). In general, MMP-13 promoter activity was elevated ∼3 to 4
fold higher when the ABCD mutant of ER-α was the modulator as
compared to the WT–ERα, across the concentration range assessed.
HIG-82 cells transfected with only the p370-Luc construct (1.0 μg) and
the internal control plasmid, pRLSV40 (0.05 μg) were used as a control
and very low levels of MMP-13 activity were detected. These results
indicate that when the AF-2/Ligand binding domains were deleted
from ER-α constructs, a greater stimulation of MMP-13 promoter
activity was observed than with equivalent doses of WT–ERα.
3.3. Comparing the inﬂuence of increasing concentration of WT–ERα
and ΔAB DNA on MMP-13 promoter activity
Next, the effect of increasing concentrations of WT–ERα DNA was
compared with the inﬂuence of ΔAB on MMP-13 promoter activity.
HIG-82 cells were transiently transfected with either WT–ERα or ΔAB
at increasing DNA concentrations ranging from 0 to 1 μg, concurrent
with the p370-Luc construct (1.0 μg) and the internal control plasmid,
pRLSV40 (0.05 μg). After 24 h, the luciferase activity of the cell lysates
were determined. In the absence of exogenous WT–ERα or ΔAB,
minimal MMP-13 promoter activity was again detectable (see Fig. 3).
The results presented in Fig. 3 demonstrate that increasing
concentrations of WT–ERα DNA again led to corresponding elevations
in MMP-13 promoter activity. However, no signiﬁcant stimulation in
MMP-13 promoter activity was observed when ΔAB was the
modulator, even when ΔAB levels were increased to 1 μg. In contrast,
in the positive controls a 5-fold increase in MMP-13 promoter activity
was observed when 0.25 μg of WT–ERα was used. Furthermore,
increasing the amount of WT–ERα DNA, to 0.5 and 1 μg led to ∼9 and
∼11 fold elevations in the activity of MMP-13 (see Fig. 3). These results
indicate that the presence of the AF-1 domain of ER-α is essential for
up-regulating the activity of the MMP-13 promoter.
3.4. Inﬂuence of progressive deletions in the AF-1 domain of ER-α on
MMP-13 promoter activity
The studies described above indicated a strong positive inﬂuence
of the AF-1 domain of ER-α on the activity of the MMP-13 promoter.
To further characterize the AF-1 domain for its role in mediating the
215Y. Achari et al. / Biochimica et Biophysica Acta 1792 (2009) 211–220effects of ER-α, a series of progressive AF-1 deletion constructs that
led to deletion of regions corresponding to the N-terminal 40, 86, 108
or 180 amino acids, were utilized [28].; see Fig. 4 panel A). The
complete N-terminal AF-1 domain of ER-α encompasses amino acids
1–180 [20]. The deletion construct E41 is missing the bases
corresponding to the ﬁrst 40 amino acids of the AF-1 domain, A87 is
missing the bases corresponding to the ﬁrst 86 amino acid residues,
M109 lacks the bases corresponding to the ﬁrst 108 amino acid
residues, and ΔAB is devoid of the entire AF-1 domain (bases
corresponding to the 180 amino acids of the N-terminal region).
These constructs were evaluated using transient transfection
assays in HIG-82 cells. The HIG-82 cells were transfected with p370-
Luc (1 μg), one of the deletion constructs of AF-1 domain of ER-α
(0.5 μg) and the internal control plasmid, pRLSV40 (0.05 μg) following
the FuGene 6 transfection protocol. After 24 h, the transfected cells
were lysed and analyzed for MMP-13 promoter activity using
luciferase assays.
The MMP-13 promoter activity observed with WT–ERα was set at
100% as presented in Fig. 5B. When the E41 construct of ER-α was
used, a mean 23% decrease in MMP-13 promoter activity was
observed. Use of the A87 deletion construct led to a mean 55%Fig. 4. Inﬂuence of AF-1 domain of ER-α on the MMP-13 promoter activity in the
presence and absence of estrogen. (A) Diagrammatic representation of theWT- ERα and
mutant constructs with progressive deletions in the A/B domain of ER-α used in the
study. (B) Progressive deletion of AF-1 domain of ER-α leads to corresponding decrease
in the activity of MMP-13 promoter. HIG-82 cells were transiently co-transfected with
0.5 μg WT–ERα or E41 or A87 or M109 or ΔAB DNA along with rabbit MMP-13 DNA
(p370-Luc), containing the ﬁrst 370 proximal bp. of the rabbit MMP-13 promoter fused
to the pGL2 Basic reporter gene and the internal control plasmid, pRLSV40. Cells
transfected with WT–ERα DNA were used as control. Luciferase activity was expressed
as the ratio of ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity. Values
represent the mean +/− S.E. for three determinations and are expressed as percentage of
p370-Luc Luciferase activity+WT–ERα DNA. ( P valuesb0.05: signiﬁcant difference
observe when compared to the inﬂuence of WT–ERα on the activity of p370-Luc).
Fig. 5. Effect of increasing concentrations of 17-β Estradiol on MMP-13 promoter
activity when either WT–ERα or ABCD or ΔAB is the modulator. HIG-82 cells were
transiently co-transfected with 0.5 μg WT–ERα or ABCD or ΔAB DNA along with rabbit
MMP-13 DNA (p370-Luc), containing the ﬁrst 370 proximal bp. of the rabbit MMP-13
promoter fused to the pGL2 Basic reporter gene and the internal control plasmid, pRL-
SV40. Cells were treated with 17-β estradiol at concentrations ranging from 10−12 M to
10−8M for 24 h. Cells transfected withWT–ERα or ABCD orΔAB DNAwithout treatment
with any ligand were used as control. Luciferase activity was expressed as the ratio of
ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity. Values represent the
mean +/− S.E. for three determinations and are expressed as percentage of p370-Luc
Luciferase activity+WT–ERα or ABCD or ΔAB DNA without treatment with 17-β
Estradiol. (A) Increasing concentrations of estradiol leads to corresponding decreases in
the MMP-13 promoter activity when WT–ERα is the modulator. The decrease in the
MMP-13 promoter activity is observed even when very low concentration of 10−12 M
estradiol is used. †P valueb0.05 when compared to MMP-13 promoter activity without
the ligand. (B) Increasing concentrations of estradiol leads does not lead to
corresponding decreases in the MMP-13 promoter activity when ABCD is the
modulator. Lack of ligand binding/AF-2 domain in the ABCDmutant makes it indifferent
to the presence of the ligand. ●P valueb0.05 when compared to MMP-13 promoter
activity without the ligand. (C) Increasing concentrations of estradiol leads to
corresponding decreases in the MMP-13 promoter activity when ΔAB is the modulator.
Low concentration of estradiol (10−12 M) has no inﬂuence on the MMP-13 promoter
activity when ΔAB is the modulator. However, at higher concentrations of 10−10
and 10−8 M, a ∼40–50% decrease in the activity of MMP-13 promoter is observed.
‡P valueb0.05 when compared to MMP-13 promoter activity without the ligand.
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deletion in the AF-1 domain (M109 construct) led to a mean 63%
decrease in MMP-13 promoter activity, and complete elimination of
the AF-1 domain led to a mean 70% decrease in MMP-13 promoter
activity. These results indicate that progressive deletions across the
AF-1 domain of ER-α lead to an increasing loss in the ability of ER to
regulate MMP-13 promoter activity. However, even the complete
removal of the AF-1 failed to completely eliminate ER inﬂuence on
MMP-13 promoter activity, suggesting minor roles for other domains
of ER-α.
3.5. Addition of the estrogenic ligand, 17-β estradiol, leads to repression
of MMP-13 promoter activity in the presence of WT–ERα and ΔAB, but
no repression is observed when ABCD is the modulator
The above results indicated that WT–ERα and ABCD are activators
of MMP-13 transcriptional activity in the absence of any estrogenic
ligand. Interestingly, ΔAB appears to be a very poor modulator of
MMP-13 promoter activity under the same conditions. Subsequently,
the inﬂuence of the estrogenic ligand, 17-β estradiol, was assessed for
impact on WT–ERα, ABCD, or ΔAB mediated alterations in MMP-13
promoter activity. The HIG-82 cells were transfected with p370-Luc
(1 μg), WT–ERα or ABCD or ΔAB (0.5 μg) and the internal control
plasmid, pRLSV40 (0.05 μg) following the FuGene 6 transfection
protocol. One set of transfected cells remained untreated, while
other sets were exposed to increasing concentrations of 17-β estradiol
(10−12, 10−10 and 10−8 M).
As shown in Fig. 5A, in the presence of WT–ERα alone, MMP-13
promoter activity was again elevated. However, an approximately
∼60% decrease inMMP-13 promoter activitywas observedwhen 10−12M
17-βestradiolwas added (see Fig. 5A). Following further increases to10−10
or 10−8 M estradiol, ∼78 and 75% decreases in MMP-13 promoter
activity were observed, respectively, with WT–ERα (see Fig. 5A). These
results suggest that increasing concentrations of 17-β estradiol led to a
relative decrease in MMP-13 promoter activity in the presence of WT–
ERα. Further, this experiment also indicated that 10−8 M 17-β estradiol is
likely a saturating amount of hormone for the amount of receptor
generated in the transfection experiments.
Consistent with the absence of the ligand binding domain,
increasing concentrations of estradiol did not lead to decreases in
MMP-13 promoter activity when ABCD was the modulator. MMP-13
promoter activity was again found to be elevated in the presence of
ABCD when no estrogenic ligand was present. However, addition of
increasing concentrations of 17-β estradiol did not lead to any
signiﬁcant decreases in MMP-13 promoter activity (see Fig. 5B), as
would be predicted because of the lack of a hormone binding domain.
While the ΔAB construct exhibited very modest inﬂuences on
MMP-13 promoter activity (Fig. 3), addition of 17-β estradiol did
however exert a detectable effect on this residual activity, but only at
the highest concentrations of estradiol tested (Fig. 5C). Thus, at
concentrations of 10−10 and 10−8 M 17-β estradiol, the ΔAB mediated
MMP-13 promoter activity decreased by approximately 60 and 50%,
respectively. Therefore, while the inﬂuence of the mutant ΔAB
construct on MMP-13 promoter activity was considerably less than
that of the WT–ERα, it was still modulated further by 17-β estradiol,
consistent with the presence of the ligand binding domain in this N-
terminally truncated ER.
3.6. Functional characterization of the MMP-13 promoter when
modulated by WT–ERα, ABCD or ΔAB
The results of the previous experiments demonstrated that MMP-
13 promoter activity is modulated differently by WT–ERα, ABCD or
ΔAB in the presence and absence of estrogen. The next step was to
identify the speciﬁc elements in the MMP-13 promoter that play a role
in ER-α mediated activity. The previously generated MMP-13 mutantpromoter constructs [16] were used for these studies (see Fig. 6A). In
order to characterize the role of promoter elements of the rabbit
MMP-13, DNA constructswith speciﬁc regulatory sitesmutated (Runx:
M370R2; PEA-3: M370P2; AP-1: M370A3 and AP-1+Runx+PEA-3:
M370A3R2P2) were transiently transfected into the HIG-82 cells along
with either the WT, ABCD, or ΔAB mutants of ERα and the internal
control plasmid, pRLSV40.
3.6.1. Modulation of MMP-13 promoter activity by WT–ERα
In the presence of WT–ERα, the MMP-13 promoter constructs
exhibited varying degrees of activity proportional to the presence and
role of each regulatory site. Maximum activity of the promoter was
achieved when theMMP-13 promoter construct (p370-Luc) contained
all the known transcription factor binding sites— the Runx, p53, PEA-
3 and AP-1 sites. The activity level of cells transfected with wild type
MMP-13 promoter (p370-Luc) was used as a control for this
experiment and activity was set at 100%.
Site directed mutations in the Runx domain changed the normal
Runx site of (AACCACA) to (AGACACA). As shown in Fig. 6B, a 22%
decrease in luciferase activity was observed when only the Runx site
was mutated (M370R2) compared to the activity levels of WT370
(Fig. 6B). The promoter activity ofWT370 decreased by 60%when 17-β
estradiol was present (Fig. 6B). In the presence of estradiol, the
residual promoter activity of M370R2 decreased by 43%, compared to
its activity in the absence of ligand (Fig. 6B).
Mutations in the PEA-3 site, which changed the sequence from
AGGAAGC to AACAAGC (M370P2), resulted in a ∼25% decrease in
activity of the MMP-13 promoter when compared to control values
(Fig. 6B). Addition of estradiol led to a ∼52% decline in residual
M370P2 activity as compared to its activity in the absence of any
ligand. These results indicate that mutation in either the Runx or the
PEA-3 site leads to similar decreases inMMP-13 promoter activity, and
that estradiol was still an effective modulator of ER activity.
The AP-1 site was mutated in M370A3 and three bases were
mutated to change the sequence from TGACTCA to ACTCTCA. A
signiﬁcant reduction in the activity of the MMP-13 promoter was
observed (∼87%) when the AP-1 domainwas mutated as compared to
the WT370 values (see Fig. 6B). Furthermore, under the inﬂuence of
17-β estradiol a further ∼50% reduction in the residual activity of the
M370A3 promoter was observed (see Fig. 6B).
Subsequently, the effect of mutating all three of the regulatory sites
in the same construct was examined. Evenwhen all three sites, i.e. AP-
1, PEA-3 and Runx (M370A3P2R2) were mutated, MMP-13 promoter
activity was depressed by ∼86%, which is nearly identical to that
observed for the AP-1 mutant alone (∼87%). These results indicate
that AP-1 is likely the major element in regulating MMP-13 promoter
activity in response to WT–ERα, and other domains such as Runx and
PEA-3 play minor roles in modulating its activity.
3.6.2. B. Modulation of MMP-13 promoter activity By ΔAB
As shown in Fig. 6C, the activity levels ofWT370modulated byΔAB
in the absence of any ligand was set at 100%. A ∼50% decrease in the
WT370 activity level was observed when 17-β estradiol was present
(see Fig. 6C). Next, the activity of themutantM370R2, with a mutation
in the Runx domain, or M370P2, with a mutation in the PEA-3 domain
with ΔAB (+/−) 17-β estradiol was examined. The impact of these
MMP-13 mutations was insigniﬁcant when ΔAB was the modulator
(Fig. 6C). Thus, mutations in the Runx and PEA-3 domains do not
signiﬁcantly impact MMP-13 promoter activity in the presence of the
ΔAB mutant of ER-α. The activity levels of these mutants (M370R2
and M370P2) did decrease by ∼50% in the presence of estradiol
compared to their residual activity levels in the absence of ligand (Fig.
6C, lanes 2B and lanes 3B).
A signiﬁcant decrease (N∼80%) in promoter activity was observed
when the AP-1 mutant (M370A3) was assessed along with ΔAB (+/−)
estradiol (see Fig. 6C). Similar trends in the activity were observed for
Fig. 6. Functional characterization of the MMP-13 promoter when modulated by either WT–ERα or ABCD or ΔAB mutant of ER-α. (A) Data showing the primary sites that were
mutated by site directed mutagenesis in the different constructs. (B) HIG-82 cells were transiently co-transfected with wild-type and site-directed mutant constructs of rabbit MMP-
13 promoter in pGL2-Basic vector (WT370, M370R2, M370P2, M370A3 and M370A3P2R2), WT–ERα or ABCD or ΔAB constructs of ER-α and internal control plasmid, pRLSV40. Cells
were treated with 10−8 M 17-β Estradiol after transfection for a period of 24 h. Luciferase activity was expressed as the ratio of ﬁreﬂy luciferase activity and the Renilla luciferase
reporter activity. Values represent the mean +/− S.E. for three determinations and are expressed as percentage of p370-Luc luciferase activity without treatment with17-β Estradiol.
The signs (−) and (+) represent activity in the absence and presence of the ligand,17-β estradiol forWT370, M370R2, M370P2, M370A3 andM370A3P2R2 respectively. ●Pb0.05 when
compared to WT370 activity modulated by WT–ERα. ‡Pb0.005 when compared to WT370 activity modulated by WT–ERα. Pb0.0005 comparison of promoter activity of
WT370 and mutants (+/− 17-β estradiol). (C) HIG-82 cells were transiently co-transfected with wild-type and site-directed mutant constructs of rabbit MMP-13 promoter, ABCD— a
mutant construct of ER-α and internal control plasmid, pRLSV40. Cells were treatedwith 10−8M 17-β Estradiol after transfection for a period of 24 h. Luciferase activitywas expressed
as the ratio of ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity. Values represent the mean +/− S.E. for three determinations and are expressed as percentage of
p370-Luc luciferase activity without treatment with17-β estradiol. The signs (−) and (+) represent activity in the absence and presence of the ligand, 17-β estradiol for WT370,
M370R2, M370P2, M370A3 and M370A3P2R2 respectively. ‡Pb0.005. ♣Pb0.00005. Pb0.005 Comparison of promoter activity of WT370 and mutants (+/− 17-β estradiol). (D)
HIG-82 cells were transiently co-transfected with wild-type and site-directedmutant constructs of rabbit MMP-13 promoter, ABCD— amutant construct of ER-α and internal control
plasmid, pRLSV40. Cells were treated with 10−8 M 17-β Estradiol after transfection for a period of 24 h. Luciferase activity was expressed as the ratio of ﬁreﬂy luciferase activity and
the Renilla luciferase reporter activity. Values represent the mean +/− S.E. for three determinations and are expressed as percentage of p370-Luc luciferase activity without treatment
with17-β Estradiol. The signs (−) and (+) represent activity in the absence and presence of the ligand, 17-β estradiol for WT370, M370R2, M370P2, M370A3 and M370A3P2R2
respectively. ♣and ‡Pb0.005 Comparison of promoter activity of WT370 and mutants (+/− 17-β estradiol).
217Y. Achari et al. / Biochimica et Biophysica Acta 1792 (2009) 211–220the mutant, M370A3P2R2, in which all the three regulatory sites are
mutated (see Fig. 6C). Therefore, the residual activity of ΔAB on the
MMP-13 promoter was still mainly mediated via the AP-1 site.
3.6.3. C. Modulation of MMP-13 promoter activity By ABCD
As exhibited in Fig. 6D, promoter activity levels were the highest
when all the transcriptional regulatory elements were intact as in the
WT370 MMP-13 promoter construct, and when the ABCD mutant of
ER-α was the modulator, and this was not altered in the presence of
estrogen (see Fig. 6D). In contrast to ﬁndings with ΔAB and WT–ERα,
the stimulatory activity of ABCD was not affected by mutations in the
Runx (M370R2) or PEA-3 (M370P2) domains (Fig. 6D). Only when the
mutations were in the AP-1 domain did the MMP-13 construct show a
∼80% decrease in activity in the presence of ABCD (Fig. 6D). Mutations
in all three transcriptional regulatory motifs did not lead to further
decreases in the activity of the MMP-13 promoter (see Fig. 6D), and
the results were similar to those observed for M370A3 alone.Furthermore, no decreases in the activity of either the WT370 or
themutantM370R2, M370P2 andM370A3 promoters was observed in
the presence of the ligand, 17-β estradiol when ABCD was the
modulator (see Fig. 6D). These results again indicate that the ABCD
construct is unable to respond to 17-β estradiol and that the AP-1
regulatory site of MMP-13 is the major regulatory site required for
mediating the effects of ABCD (+/−) ligand.
4. Discussion
The results presented in this study in synoviocyte cells suggest that
both AF-1 and AF-2/ligand binding domains of ER-α play a role in
modulating the activity of the MMP-13 promoter. Complete deletion
of the AF-1 domain of ER-α (ΔAB construct) led to signiﬁcant
reductions in MMP-13 promoter activity when compared to the
inﬂuence ofWT–ERα onMMP-13 activity (see Fig. 3B). Since the AF-2/
ligand binding domain is intact in the ΔAB construct, it is still able to
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hormone led to decreases in the residual MMP-13 promoter activity
(see Fig. 4C). Conversely, a constitutive elevation in the activity of the
MMP-13 promoter was observed when the ABCD mutant ER with a
deletion of the AF-2/ligand binding domain was used as the
modulator. As expected, no decreases in the activity of the MMP-13
were observed when 17-β estradiol was present with ABCD as the
modulator. Furthermore, similar protein expression of ABCD, ΔAB and
WT–ERαwas detected inwestern blot analysis; thereby ruling out the
possibility that overexpression of ABCD can lead to higher activity of
MMP-13. Our analysis of the MMP-13 promoter through site-directed
mutagenesis studies have shown that regulation of MMP-13 promoter
activity by WT, ABCD or ΔAB constructs of ER-α occurred primarily
through the AP-1 transcriptional regulatory site. However, for full
induction of MMP-13 promoter activity, other regulatory sites such as
Runx and PEA-3 also contributed in a minor fashion to the activation
elicited by ER-α.
Previous studies have shown that both AF-1 and AF-2 regions of
ER-α are required for full ER activity in most cellular systems [23,30].
Moreover, it is alsowell recognized that the activation function of both
the AF-1 and AF-2 domains of ER-α vary in a promoter and cell type
speciﬁc manner [30–32]. Previous reports have shown that the
activity of the AF-2 domain is controlled by the hormone, estrogen
[30]. The ABCDmutant of ER-α used in this study lacks the AF-2/ligand
binding domain. Therefore, decreases in MMP-13 activity in the
presence of 17-β estradiol were not observed when ABCD was the
modulator. The present observations are further corroborated by
studies reported by An et al. [33] which suggested that the AF-2
domain is required for the estrogen mediated transcriptional repres-
sion of TNF-α since mutations in the AF-2 domain impair this
repression.
Using both western blot analysis and immunohistochemistry
previous observations have suggested that the HIG-82 cell line is
devoid of detectable endogenous ER [16]. Therefore, the inﬂuence of
endogenous ER-α on the MMP-13 promoter activity can be ruled out.
The results obtained from real time PCR experiments indicated that
endogenous MMP-13 activity is stimulated byWT–ERα and the ABCD
mutant, but not the ΔAB mutant, when they are introduced into the
HIG-82 cell line (see Fig. 1). The HIG-82 cell line which usually
demonstrates a low constitutive expression of MMP-13 mRNA,
showed a ∼2-fold increase in the presence of WT–ER-α, and when
the ABCD mutant of ER-α was the modulator, a ∼4-fold increase in
endogenous MMP-13 mRNA was observed.
In the present studies, MMP-13 promoter activity was found to be
very low when ΔAB was the modulator as compared to the inﬂuence
of the WT–ERα (see Fig. 3B). The ΔAB is a deletion mutant of ER-α
which is missing the entire AF-1 domain. The AF-1 domain is well
characterized as the ligand independent transactivation domain of the
ER-α and is speculated to synergize with the AF-2 domain to elicit the
overall estrogen response on promoters containing classical estrogen
response elements (ERE) [20,30,34]. Recently, it was shown that the
cyclin G2 gene is down-regulated by ER-α when it is occupied by
estrogen [35]. Furthermore, a detailed mutational analysis of the ER-α
revealed the necessity of the N-terminal region and the DNA binding
domain to sustain the cyclin G2 repression. The present study also
showed that progressive deletion of the AF-1 domain of ER-α led to
corresponding decreases in the activity of the MMP-13 promoter. It
appears that even the deletion of the equivalent of the ﬁrst 40 amino
acids from the N-terminal portion of the ER-α is sufﬁcient to result in
signiﬁcant decreases in the stimulatory activity of ER-α on the MMP-
13 promoter (see Fig. 5B). These results are further substantiated by
other studies which have shown that the ﬁrst 21 amino acids of the
AF-1 domain of ERα are required for cyclin G2 repression [35].
It has been speculated that in some cell types only one of the two
AF domains may play a role in modulating the transcriptional activity
due to the speciﬁc expression of distinct coactivators [20]. Further-more,Webb et al. [20] have demonstrated that themore differentiated
a cell is, the more likely that it will use the AF-1 domain of ER-α to
mediate estrogen responses, and undifferentiated and dedifferen-
tiated cells tend to depend more on the AF-2 domain of ER-α. The
rabbit synoviocytes used in the present study can likely be classiﬁed as
a differentiated cell line and the results presented in the present study
show a deﬁnite lack of in stimulatory activity when the ΔAB construct,
missing the AF-1 domain, is used as a modulator. Therefore, it is likely
that the AF-1 domain of ER-α plays the major positive regulatory role
in modulating the activity of MMP-13. However, since the absence of
the AF-2/ligand binding domain leads to signiﬁcant elevations in the
stimulatory activity of the ABCD construct, a distinct negative
regulatory role can also likely be assigned to the AF-2 domain.
The inﬂuence of ER on estrogen responsive genes can be mediated
either through an estrogen response element (ERE), AP-1, or other
sites in the promoter of target genes [21,36]. The rabbit MMP-13
promoter used in the present studies is well characterized and lacks
the conventional ERE sequence, although it does have an AP-1 site.
Other major transcriptional regulatory sites present include the Runx
domain, PEA-3 site and p53 site. Previous studies performed by our
group have indicated that the AP-1 site of the rabbit MMP-13
promoter acts in conjunction with other regulatory sites such as the
PEA-3 and Runx domains for mediating the effects of 17-beta estradiol
in the presence of intact ER-α [16]. These studies have been performed
with MMP-13 promoter ranging from 670 bps to approximately
43 bps. The premise of tissue-speciﬁc expression ofMMPs is becoming
increasingly popular [37]. The restricted expression of MMP-13 in
cartilage and bone has been attributed to the Runx-2 site present in
the promoter of MMP-13 [38]. The protein binding to the Runx-2 site
has primarily been found in bone and cartilage cells. This site is
considered essential for the optimal expression of MMP-13. Studies in
both the human and rabbit genes have established the requirement of
the AP-1 and Ets families of transcription factors that bind to their
cognate sites just upstream of the TATA box [39–41]. Furthermore, the
activation of theMMP-13 promoter by p38 through recruitment of AP-
1 and the transcription factor Runx-2 in chondrocytes further
emphasizes the tissue-speciﬁc mechanisms regulating MMP-13 gene
expression [38],
The present study demonstrates that the AP-1 site of the MMP-13
promoter is also likely the primary locus for mediating the effects of
WT–ERα, as well as the mutants ABCD and ΔAB in the presence and
absence of the estrogenic ligand 17-β estradiol. Interestingly,
mutations in the Runx and PEA-3 domains of the MMP-13 promoter
did not appear to have a signiﬁcant impact on the stimulatory activity
of ABCD. Only mutations in the AP-1 domain led to signiﬁcant
decreases in the activity of the MMP-13 promoter when the ABCD
construct of ER-α was the modulator (see Fig. 6D). In contrast to
these observations, mutations in the Runx and PEA-3 domains did
lead to modest, but signiﬁcant decreases in stimulation of MMP-13
promoter activity when ΔAB or WT–ERα were present as stimulators
(see Fig. 6B and C).
Previous studies by Mengshol et al. [38] have shown that the
transcriptional response of MMP-13 to IL-1 in chondrocytes requires
transcription factors that can bind to AP-1 and Runx-2. In a separate
study, the AP-1 and Runx domain transcriptional factor binding sites
on the rat MMP-13 promoter have been shown to be essential in both
parathyroid hormone (PTH)-treated and differentiating osteoblastic
cells in vitro [42,43]. Furthermore, it has been demonstrated that the
Runx domain and AP-1 binding sites are organized in a speciﬁc helical
pattern that facilitates the interaction of proteins that bind to these
sites leading to the activation of the MMP-13 promoter activity [44].
Thus, the AP-1 site in conjunction with other transcription factor
binding sites appears to be critical for the transcriptional regulation of
MMP-13 by some stimuli in certain cells, but the AP-1 site appears to
be the dominant site for modulation of theMMP-13 promoter by ER-α
in the HIG-82 cells.
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estrogen aremediated through either the alpha or the beta isoforms of
ER. In addition to ER-α and ER-β, recently attention has turned to
estrogen receptor related proteins (ERRs) which are classiﬁed as
orphan receptors, as ligands which bind to these receptors have not
been identiﬁed and they do not bind the naturally occurring
endogenous estrogens (reviewed in [45]). ERRs have been implicated
in the development of breast cancer, as they are postulated to interfere
with the estrogen signaling in the breast tissues [46]. Although the
presence of ERRs has been established in bone [47], cartilage [25] and
in connective tissues such as ligaments [11], it is unknown if they play
any role in the development of joint diseases such as osteoarthritis. As
the present study has shown that ER constructs containing the AF-1
domain but lacking the ligand binding domain can effectively
modulate MMP-13 promoter activity, ERs altered in or lacking ligand
binding domains could potentially play a role in a variety of conditions
to regulate expression of some genes.
In summary, the present study has characterized the requirements
for ER-α modulation of the rabbit MMP-13 promoter in a transient
transfection system. The results indicate that speciﬁc domains of the
ER-α, and especially the AF-1 domain, are critical for activity and that
the ligand binding/AF-2 domain likely serves a modulating role. The
ﬁndings also support the concept that naturally occurring ER-α
proteins lacking ligand binding ability and thus modulation by
estrogen, could also play a role in regulating gene expression in
disease processes.
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